Why these ASX growth shares could rise 30%+

Analysts think these shares are undervalued. Let's see what they are saying.

| More on:
A man sees some good news on his phone and gives a little cheer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you have a penchant for ASX growth shares like I do, then read on!

That's because the two in this article have not only been named as buys but have been tipped to rise at least 30% from current levels. Here's what analysts are saying about them:

Life360 Inc (ASX: 360)

The team at Goldman Sachs thinks that this location technology company could be a quality ASX growth share to buy now.

It has a buy rating and $27.00 price target on its shares. This suggests that upside of 30% is possible for investors between now and this time next year.

The broker likes Life360 due to its huge total addressable market (TAM) and significant user monetisation opportunity. It explains:

We estimate Life360 is exposed to a US$12bn global TAM with a large opportunity to expand its product suite, grow average revenue per paying circle (ARPPC), increase payer conversion, and lift penetration rates outside of the US. The company has demonstrated its pricing power and is now exploring the latent monetisation opportunity of its >60mn user base via advertising.

Goldman also highlights that its shares are undervalued compared to peers. It adds:

 Life360's Subscription business currently trades at a discount to global subscription app peers when adjusting for its superior growth outlook. We see scope for re-rating as Life360 demonstrates operating leverage, ongoing subscription growth and user monetisation via ads. We are Buy rated on Life360.

Pro Medicus Limited (ASX: PME)

Bell Potter thinks that this health imaging technology company could be an ASX growth share to buy.

Its analysts have put a buy rating and $280.00 price target on its shares. Based on its current share price, this implies potential upside of 33% over the next 12 months.

Commenting on the company, the broker said:

Pro medicus is a leading health imaging IT provider. It's leading product is the Visage 7 Enterprise Viewer (the Visage Viewer). It is an essential component of a modern PACS with its main advantage being speed. Using this system the radiologist is able to view medical images from all major modalities at lightning fast speed including prior exams.

Visage 7 is the fastest, most versatile viewing software on the market and it is the key reason why Pro medicus has been successful in winning numerous high profile hospital contracts in the US, ahead of some of the largest global names in the industry.

Motley Fool contributor James Mickleboro has positions in Life360 and Pro Medicus. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and Life360. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Growth Shares

Why these ASX 200 shares could still have major upside in 2026

Brokers think these shares could rise 20% to 45% in 2026.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Growth Shares

How I'd look for ASX growth shares today that could double my money

It might not be as hard as you think to achieve this.

Read more »

A group of young ASX investors sitting around a laptop with an older lady standing behind them explaining how investing works.
Growth Shares

3 unstoppable ASX growth stocks to buy even if there's a stock market sell-off in 2026

Market volatility is uncomfortable, but some businesses are built to keep growing regardless of sentiment.

Read more »

A woman rides through an office on a scooter with a rocket strapped to her back as colleagues cheer.
Growth Shares

2 ASX growth shares set to skyrocket in 2026 and beyond

When sentiment turns, quality growth stocks often get dragged down.

Read more »

A business person directs a pointed finger upwards on a rising arrow on a bar graph.
Growth Shares

5 top ASX growth shares to buy now with $5,000

These shares are rated as buys by brokers. Here's what they are recommending.

Read more »

The hands of three people are cupped around soil holding three small seedling plants that are grouped together in the centre of the shot with the arms of the people extending into the edges of the picture representing ASX growth shares and it being a good time to buy for future gains
Dividend Investing

3 ASX shares that I rate as buys for both growth and dividends

These businesses could provide excellent total returns.

Read more »

A man peers into the camera looking astonished, indicating a rise or drop in ASX share price
Growth Shares

2 no-brainer Australian stocks to buy with $1,000 right now

Brokers believe these buy-rated shares could rise over 50% from current levels.

Read more »

A man and woman sit next to each other looking at each other and feeling excited and surprised after reading good news about their shares on a laptop.
Growth Shares

The best ASX stocks to buy in January 2026 if you want both income and growth

These shares offer the winning combination of income and growth.

Read more »